Published in Mol Cancer Res on July 01, 2008
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics (2010) 2.26
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res (2011) 1.34
The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem (2011) 1.20
Identification of PADI2 as a potential breast cancer biomarker and therapeutic target. BMC Cancer (2012) 1.18
mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. Breast Cancer Res Treat (2014) 0.94
HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade. Oncogene (2013) 0.94
Integrated analysis of recurrent properties of cancer genes to identify novel drivers. Genome Biol (2013) 0.91
HDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. PLoS One (2013) 0.87
Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J Pathol (2011) 0.85
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast. J Breast Cancer (2014) 0.85
HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Mol Cancer Ther (2013) 0.85
Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305. Mol Cancer Res (2012) 0.83
Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Cancer Biol Ther (2014) 0.81
ErbB3-binding protein EBP1 decreases ErbB2 levels via a transcriptional mechanism. Oncol Rep (2012) 0.81
Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells. Biomed Res Int (2014) 0.79
RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth. Oncotarget (2014) 0.78
Insights from the HuR-interacting transcriptome: ncRNAs, ubiquitin pathways, and patterns of secondary structure dependent RNA interactions. Mol Genet Genomics (2012) 0.77
NIK is required for NF-κB-mediated induction of BAG3 upon inhibition of constitutive protein degradation pathways. Cell Death Dis (2015) 0.76
Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment. Neoplasia (2016) 0.75
MRGBP as a potential biomarker for the malignancy of pancreatic ductal adenocarcinoma. Oncotarget (2017) 0.75
HDAC6 is a microtubule-associated deacetylase. Nature (2002) 12.76
AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res (2006) 6.22
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A (2003) 5.56
Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell (2002) 5.19
Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci U S A (2004) 5.15
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem (2006) 4.59
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol (2008) 2.85
A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J Biol Chem (1999) 2.82
Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol (2007) 2.25
Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res (2005) 1.94
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene (2005) 1.79
HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res (2004) 1.74
AMP-activated protein kinase-regulated phosphorylation and acetylation of importin alpha1: involvement in the nuclear import of RNA-binding protein HuR. J Biol Chem (2004) 1.46
HDAC6 a new cellular stress surveillance factor. Cell Cycle (2007) 1.40
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell (2006) 1.29
HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol (2005) 1.27
Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol (2007) 1.04
Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res (2005) 1.03
Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol Cancer Ther (2002) 0.99
Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases. Anal Biochem (2003) 0.89
Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription. Assay Drug Dev Technol (2006) 0.86
A homogeneous nonisotopic histone deacetylase activity assay. J Biomol Screen (2003) 0.79
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell (2003) 8.34
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol (2007) 7.97
SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature (2010) 6.48
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci U S A (2006) 5.96
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer (2006) 5.47
The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol (2002) 5.37
Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell (2002) 5.19
Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab (2010) 4.97
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem (2006) 4.59
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35
Conserved metabolic regulatory functions of sirtuins. Cell Metab (2008) 3.86
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science (2012) 3.52
Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res (2009) 3.40
SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell (2011) 3.33
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol (2004) 3.00
Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci U S A (2007) 2.97
The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics (2011) 2.83
Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res (2006) 2.83
SIRT3 deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and regulates ketone body production. Cell Metab (2010) 2.77
Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol Cell Proteomics (2012) 2.66
CpG methylation controls reactivation of HIV from latency. PLoS Pathog (2009) 2.51
Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog (2009) 2.50
Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol (2011) 2.49
Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem (2004) 2.47
Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J Biol Chem (2007) 2.37
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics (2010) 2.26
SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol (2005) 2.24
Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell (2002) 2.20
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev (2008) 2.12
HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity (2003) 2.10
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J (2002) 2.06
First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. Cancer Causes Control (2014) 2.05
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene (2002) 2.02
Label-free quantitative proteomics of the lysine acetylome in mitochondria identifies substrates of SIRT3 in metabolic pathways. Proc Natl Acad Sci U S A (2013) 2.01
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle (2012) 1.88
The nexus of chromatin regulation and intermediary metabolism. Nature (2013) 1.87
Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci U S A (2008) 1.80
Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem (2004) 1.79
The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem (2006) 1.77
The Cellular lysine methyltransferase Set7/9-KMT7 binds HIV-1 TAR RNA, monomethylates the viral transactivator Tat, and enhances HIV transcription. Cell Host Microbe (2010) 1.76
miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Aging (Albany NY) (2010) 1.76
SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks. Cell Metab (2013) 1.70
Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J (2005) 1.70
The serum response factor and a putative novel transcription factor regulate expression of the immediate-early gene Arc/Arg3.1 in neurons. J Neurosci (2009) 1.69
Mitochondrial sirtuins. Biochim Biophys Acta (2010) 1.67
The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem (2009) 1.64
Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases. J Biol Chem (2002) 1.62
Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. J Biol Chem (2012) 1.58
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer (2007) 1.57
The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats. Kidney Int (2011) 1.56
Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent phosphorylation. J Biol Chem (2007) 1.55
Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol Metab (2012) 1.52
Immunosenescence and HIV. Curr Opin Immunol (2012) 1.51
Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One (2007) 1.50
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res (2010) 1.50
Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J (2002) 1.49
MicroRNAs of the miR-17∼92 family are critical regulators of T(FH) differentiation. Nat Immunol (2013) 1.48
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
The nephronophthisis gene product NPHP2/Inversin interacts with Aurora A and interferes with HDAC6-mediated cilia disassembly. Nephrol Dial Transplant (2013) 1.47
Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol (2004) 1.45
Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J Biol Chem (2011) 1.43
Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol Cell (2003) 1.42
Mitochondrial acetylome analysis in a mouse model of alcohol-induced liver injury utilizing SIRT3 knockout mice. J Proteome Res (2012) 1.41
Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism. Nat Chem Biol (2012) 1.39
Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat (2011) 1.39
Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol (2013) 1.35
Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett (2007) 1.34
Regulatory signal transduction pathways for class IIa histone deacetylases. Curr Opin Pharmacol (2010) 1.34
Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer (2010) 1.32
Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer (2008) 1.32
Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J Med Chem (2008) 1.31
Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases. Int J Cancer (2007) 1.30
Myosin phosphatase dephosphorylates HDAC7, controls its nucleocytoplasmic shuttling, and inhibits apoptosis in thymocytes. Genes Dev (2007) 1.29
SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta (2011) 1.28
Targeted quantitation of site-specific cysteine oxidation in endogenous proteins using a differential alkylation and multiple reaction monitoring mass spectrometry approach. Mol Cell Proteomics (2010) 1.26
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res (2004) 1.26
Subtype selective substrates for histone deacetylases. J Med Chem (2004) 1.25
ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res (2010) 1.24
Acetylation of mitochondrial proteins. Methods Enzymol (2009) 1.24
Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol (2005) 1.23
Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood (2003) 1.23
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem (2002) 1.23
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 1.23
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther (2007) 1.22